



Received on 06 November, 2011; received in revised form 20 February, 2012; accepted 25 February, 2012

ETHOSOMES AS ELASTIC VESICLES IN TRANSDERMAL DRUG DELIVERY: AN OVERVIEW

N. B. Gupta*, S. Loona and M. U. Khan

Department of Pharmaceutics, Sri Sai College of Pharmacy, Badhani, Pathankot (Punjab)- 145001

ABSTRACT

Keywords:

Ethosomes,
Liposomes,
Vesicles,
Drug penetration,
Stability,
Transdermal drug delivery

Correspondence to Author:

Nitan Bharti


Assistant Professor, Department of
Pharmaceutics, Sri Sai College of
Pharmacy, Badhani, Pathankot, Punjab,
India

Ethosomes are as novel vesicles in transdermal drug delivery show significant effects of drug penetration through the biological membrane with slight modification of well established drug carrier liposomes. Ethosomes are soft, malleable vesicles composed mainly of phospholipids, ethanol and water. The size of ethosome vesicles can be modulated from tens of nanometer to microns. The ethosomes can be prepared by Hot as well as Cold method. The evaluation parameters of ethosomes include visualization, vesicle size and zeta potential, transition temperature, surface tension activity measurement, vesicle stability, drug content, penetration and permeation studies. Ethosomes have been found to be much more efficient at delivering drug to the skin than either liposomes or hydroalcoholic solution. Thus, it can be a logical conclusion that ethosomal formulation possesses promising future in effective dermal/transdermal delivery of bioactive agents.


INTRODUCTION: Transdermal administration of drugs is generally limited by the barrier function of the skin. Vesicular systems are one of the most controversial methods for transdermal delivery of active substances¹. The interest in designing transdermal delivery systems was relaunched after the discovery of elastic vesicles: Ethosomes. Ethosomes are novel carrier system used for delivery of drugs having low penetration through the biological membrane mainly skin. Ethosomes are the slight modification of well established drug carrier liposomes².

Ethosomes: Ethosomes are lipid vesicles containing phospholipids, alcohol (ethanol and isopropyl alcohol) in relatively high concentration and water³. Ethosomes are soft vesicles made of phospholipids and ethanol (in higher quantity) and water. The size range of ethosomes may vary from tens of nanometers to microns (μ)⁴. Ethosomes permeate through the skin layers more rapidly and possess significantly higher

transdermal flux in comparison to conventional liposomes^{4, 5}. Visualization of ethosomes is shown in **Figure 1**. Although, the exact mechanism for better permeation into deeper skin layers from ethosomes is still not clear. The synergistic effects of combination of phospholipids and high concentration of ethanol in vesicular formulations have been suggested to be responsible for deeper distribution and penetration in the skin lipid bi-layers.



VISUALIAZATION OF ETHOSOME (TEM MAGNIFICATION: 315000)



VISUALIAZATION OF ETHOSOME
(SEM X 100, 000)

FIGURE 1: VISUALIZATION OF ETHOSOMAL VESICLES

Composition: The ethosomes are vesicular carrier comprise of hydroalcoholic or hydro/alcoholic/glycolic phospholipid in which the concentration of alcohols or their combination is relatively high. Typically, ethosomes may contain phospholipids with various chemical structures like phosphatidylcholine (PC), hydrogenated PC, phosphatidic acid (PA), phosphatidylserine (PS), phosphatidylethanolamine (PE), phosphatidylglycerol (PPG), phosphatidylinositol (PI), hydrogenated PC, alcohol (ethanol or isopropyl alcohol), water and and propylene glycol (or other glycols) ^{6,7}.

Such a composition enables delivery of high concentration of active ingredients through skin. Drug delivery can be modulated by altering alcohol: water or alcohol-polyol: water ratio. Some preferred phospholipids are soya phospholipids such as Phospholipon 90 (PL-90). It is usually employed in a range of 0.5-10% w/w. Cholesterol at concentrations ranging between 0.1-1 percent can also be added to the preparation¹. Examples of alcohols, which can be used, include ethanol and isopropyl alcohol. Among glycols, propylene glycol and Transcutol are generally used.

In addition, non-ionic surfactants (PEG-alkyl ethers) can be combined with the phospholipids in these preparations. Cationic lipids like cocoamide, POE alkyl amines, dodecylamine, cetrimide etc. can be added too. The concentration of alcohol in the final product may range from 20 to 50%. The concentration of the non-aqueous phase (alcohol and glycol combination) may range between 22 to 70% ^{8,9}. Different additives used in the ethosomal formulation are presented in the **table 1**.

TABLE 1: TABULAR FORM REPRESENTS DIFFERENT ADDITIVES USED IN THE ETHOSOMAL FORMULATION

Class	Examples	Uses
Phospholipids	Soya phosphatidyl choline; Egg phosphatidyl choline; Diestearyl phopshatidyl choline	Vesicle forming components
Polyglycerol	Propylene glycol; Transcutol RTM	As a skin penetration enhancer
Alcohol	Ethanol; Isopropyl alcohol	For providing the softness for vesicle membrane; As a skin penetration enhancer
Cholesterol	Cholesterol	For providing the stability for vesicle membrane
Dyes	Rhodamine 123; Rhodamine red	For characterization studies
Vehicles	Carbopol D934	As a gel former

Advantages of Ethosomal Drug Delivery ^{3, 10, 11}: In comparison to other transdermal & dermal delivery system;

- Ethosomes have enhanced permeation of drug through skin for transdermal drug delivery.
- The delivery of large molecules (peptides, protein molecule) is possible.
- It contains non-toxic raw material in formulation.
- High patient compliance- The ethosomal drug is administrated in semisolid form (gel or cream) hence producing high patient compliance.

- The Ethosomal system is passive, non-invasive and is available for immediate commercialization.
- Ethosomal drug delivery system can be applied widely in Pharmaceutical, Veterinary, Cosmetic fields.
- Simple method for drug delivery in comparison to Iontophoresis and Phonophoresis and other complicated methods.

Mechanism of Drug Penetration ¹²: The main advantage of ethosomes over liposomes is the increased permeation of the drug. The mechanism of the drug absorption from ethosomes is not clear. The drug absorption probably occurs in following two phases ^{13, 14} (**Figure 2**):

1. Ethanol Effect: Ethanol acts as a penetration enhancer through the skin. The mechanism of its penetration enhancing effect is well known. Ethanol penetrates into intercellular lipids and increases the fluidity of cell membrane lipids and decrease the density of lipid multilayer of cell membrane.

2. Ethosomal Effect: Increased cell membrane lipid fluidity caused by the ethanol of ethosomes results increased skin permeability. So the ethosomes permeates very easily inside the deep skin layers, where it got fused with skin lipids and releases the drugs into deep layer of skin.




FIGURE 2: DIAGRAMMATICALLY REPRESENTATION OF MECHANISM OF ACTION OF ETHOSOMES

Method of Preparation^{4, 8, 15}: There are two methods which can be used for the formulation and preparation of ethosomes. Both of the methods are very simple and convenient and do not involve any sophisticated instrument or complicated process.


Ethosomes can be formulated by following two methods: The formulation of ethosomes involves hot and cold method (see table 2)

1. Hot Method: In this method disperse phospholipid in water by heating in a water bath at 400°C until a colloidal solution is obtained. In a separate vessel properly mix ethanol and propylene glycol and heat up to 400°C. Add the organic phase into the aqueous phase. Dissolve the drug in water or ethanol depending on its solubility. The vesicle size of ethosomal

formulation can be decreased to the desire extent using probe sonication or extrusion method.

2. Cold Method: This is the most common and widely used method for the ethosomal preparation. Dissolve phospholipids, drug and other lipid materials in ethanol in a covered vessel at room temperature with vigorous stirring. Add propylene glycol or other polyglycol during stirring. Heat the mixture up to 300°C in a water bath. Heat the water up to 300°C in a separate vessel and add to the mixture and then stir it for 5 min in a covered vessel. The vesicle size of ethosomal formulation can be decreased to desire extend using sonication or extrusion method. Finally, the formulation should be properly stored under refrigeration.

TABLE 2: FLOW CHART REPRESENTATION OF HOT METHOD AND COLD METHOD



Evaluation: The methods of evaluation for ethosomes are discussed below:

- **Vesicle Shape**¹⁶: Ethosomes can be easily visualized by using transmission electron microscopy (TEM) and by scanning electron microscopy (SEM).
- **Vesicle Size and Zeta Potential**¹⁵: Particle size of the ethosomes can be determined by dynamic light scattering (DLS) and photon correlation spectroscopy (PCS). Zeta potential of the formulation can be measured by Zeta meter.
- **Transition Temperature**¹⁴: The transition temperature of the vesicular lipid systems can be determined by using differential scanning calorimetry (DSC).
- **Drug Entrapment**¹⁷: The entrapment efficiency of ethosomes can be measured by the ultracentrifugation technique.
- **Drug Content**¹⁸: Drug content of the ethosomes can be determined using UV spectrophotometer. This can also be quantified by a modified high performance liquid chromatographic method.
- **Surface Tension Measurement**¹⁹: The surface tension activity of drug in aqueous solution can be measured by the ring method in a Du Nouy ring tensiometer.
- **Stability Studies**²⁰: The stability of vesicles can be determined by assessing the size and structure of the vesicles over time. Mean size is measured by DLS and structure changes are observed by TEM.
- **Skin Permeation Studies**¹³: The ability of the ethosomal preparation to penetrate into the skin layers can be determined by using confocal laser scanning microscopy (CLSM).

Evaluation parameters and instrument/methods used in Ethosomes are shown in **table 3**.

TABLE 3: EVALUATION PARAMETERS AND INSTRUMENT/METHODS USED IN ETHOSOMES

PARAMETERS	INSTRUMENTS/METHODS USED	IMPORTANCE
Vesicle Shape	Transmission Electron Microscopy (TEM) Scanning Electron Microscopy (SEM)	Determines skin penetration
Vesicle Size and Zeta Potential	Dynamic Light Scattering (DLS), Photon Correlation Spectroscopy (PCS) and Zeta Meter	Determines skin penetration and stability of vesicles
Transition Temperature	Differential Scanning Calorimetry (DSC)	Determines transition temperature of lipid vesicles
Drug Entrapment	Ultracentrifugation Technique	Suitability of method
Drug Content	UV Spectrophotometer, High Performance Liquid Chromatographic Method (HPLC)	Important in deciding the amount of vesicle preparation to be used
Surface Tension Measurement	Ring Method in a Du Nouy ring tensiometer	Determines surface tension activity of drug in aqueous solution
Stability Studies	Dynamic Light Scattering (DLS), Transmission Electron Microscopy (TEM)	To determine the shelf-life of vesicle formulation
Skin Permeation Studies	Confocal Laser Scanning Microscopy (CLSM)	Determines rate of drug transport through skin
In-vitro dissolution	Franz diffusion cell	Determines the drug release rate from vesicle

Ethosomes as a Drug Carrier: Ethosomes can be used for many purposes in drug delivery. Ethosomes are mainly used as replacement of liposomes. Ethosomes

can be used for transdermal delivery of hydrophilic and impermeable drugs through the skin. Following drugs have been used with ethosomal carrier (**see Table 4**).

TABLE 4: DRUG INCORPORATED IN ETHOSOMAL CARRIER

NAME OF DRUG	DRUG INCORPORATED IN ETHOSOMAL CARRIER	USES
Acyclovir ²¹	Improved skin permeation. Improved in pharmacodynamics profile. Improved in biological activity two to three times.	Treatment of Herpes labialis
Anti-HIV agents ²² (Zidovudine, Lamivudine)	Reduced drug toxicity. Prolonging drug action. Improved transdermal flux. Affected the normal histology of skin. Improved in biological activity two to three times.	Anti-HIV
Azelaic acid ²³	Prolong drug release. Improved in biological anti-inflammatory activity.	Treatment of various inflammatory based skin diseases
Ammonium glycyrrhizinate ²⁴	Improved dermal deposition exhibiting sustained release.	
Bacitracin ²⁵	Increased bioavailability. Improved dermal deposition. Improved intracellular delivery.	Anti-bacterial
Cannabidiol ²⁶	Improve bioavailability. Increased skin permeation. Improved GIT degradation.	Treatment of Rheumatoid arthritis
Cyclosporin A ⁶	Prolong drug action. Improved bioavailability. Improved skin deposition.	Treatment of inflammatory skin diseases
DNA ⁹	Better expression of genes. Selective targeting to dermal cells.	Treatment of genetic disorders
Erythromycin ²⁷	Better cellular uptake	Anti-microbial
Fluconazole ⁷	Better skin permeation	Treatment of Candidiasis
Insulin ⁸	Provide control release. Significant decrease in blood glucose level.	Treatment of diabetes
Minoxidol ²⁸	Pilocebaseous targeting. Accumulation in skin increased significantly.	Treatment of baldness
Methotrexate ⁹	Better skin permeation	Treatment of Proriasis
NSAIDs ⁹ (Diclofenac)	Selective delivery of drug to described side for prolong period of time	Analgesic and anti-inflammatory
Testosterone ²⁹	Improved oral bioavailability. Reduced side effects.	Steroidal hormone
Trihexyphenidyl hydrochloride ¹⁸	Provide control release. Improved transdermal flux. Improved patient compliance.	Treatment of Parkinson disease
Salbutamol Sulfate ⁵	Enhanced drug delivery through skin	Anti-asthmatic

REFERENCES:

1. Ijeoma F, Uchegbu, Vyas S.P: Non-ionic surfactant based vesicles in drug delivery. *Int. J. Pharm.*, 1998; 172: 33-70.
2. Scherie H, Bouwstra J: Liposomes and niosomes as topical drug carriers- dermal and transdermal drug delivery. *J. Control. Release* 1994; 30: 1-15.
3. Patel S: Ethosomes: A promising tool for transdermal delivery of drug. *Pharma. Info. Net.* 2007; 5(3): 47-53.
4. Touitou E, Dayan N, Bergelon L., Goldin B., Eliav M: Ethosomes novel vesicular carriers for enhanced delivery, characterization and skin permeation properties, *J. Control Release* 2000; 65: 403-418.
5. Bendas E.R, Tadros M.I: Enhanced transdermal delivery of salbutamol sulfate via ethosomes. *AAPS Pharm. Sci. Tech.* 2007; 8(4): 1-15.
6. Verma D.D, Fahr A: Synergistic penetration effect of ethanol and phospholipids on the topical delivery of cyclosporine A. *J Control Release* 2004; 97: 55-66.
7. Bhalaria M.K, Nail S, Miera A.N: Ethosomes:- A novel delivery system for antifungal drugs in the treatment of topical fungal diseases. *Indian Journal of Experimental Biology* 2009; 47: 368-375.
8. Touitou E, Godin B, Dayan N, Piliponsky A, Levi Schaffer F, Weiss C: Intracellular delivery mediated by an ethosomal carrier and biomaterials 2001; 22: 3053-3059.
9. Gangwar S, Singh S, Garg G: Ethosomes: A novel tool for drug delivery through the skin. *Journal of Pharmacy Research* 2010; 3(4): 688-691.
10. Pandey N: Proniosomes and Ethosomes: New prospect in transdermal drug delivery system. *International Journal of Pharmaceutical sciences and research* 2011; 2(8): 1988-1996.
11. Anitha P, Ramkanth S, Umasankari K, Alagusundaram M, Devaki Devi P, Indira Prasanna: Ethosomes: A non-invasive vesicular carrier for transdermal drug delivery. *IJRLS* 2011; 1: 23-30.
12. Jain S, Mishra D, Kuksal A, Tiwary A.K, Jain N.K: Vesicular approach for drug delivery into or across the skin:- current status and future prospectus. www.pharmainfo.net.
13. Toll R, Jacobi U, Richter H, Lademann J, Schaefer H, Blume U: Penetration profile of microsphere in follicular targeting of terminal hair follicles. *J. Invest Dermatol* 2004; 123: 168-176.
14. New RRC, Preparation and size determination, In: *Liposomes A practical approach*, New RRC (Ed.), Oxford University Press, Oxford, 1990: 36-39.
15. Maghraby G.M.M, Williams A.C, Barry B.W: Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration. *Int. J. Pharm.* 2000; 196(1): 63-74.
16. Guo J, Ping Q, Sun G, Jiao C: Lecithin vesicular carriers for transdermal delivery of cyclosporine A. *Int. J. Pharm.* 2000; 194(2): 201-207.
17. Fry D.W, White J.C, Goldman I.D: Rapid secretion of low molecular weight solutes from liposomes without dilution. *Anal. Biochem.* 1978; 90: 809-815.
18. Dayan N, Touitou E: Carrier for skin delivery of triexyphenidyl HCL: - Ethosomes vs liposomes. *Biomaterials* 2002; 21: 168-176.
19. Cevc G, Schatzlein A, Blume G: Transdermal drug carriers:- basic properties, optimization and transfer efficiency in case of epicutaneously applied peptides. *J. Control Release* 1995; 36: 3-16.
20. Vanden B, Swartzendruber VAB, Geest J: Development of an optimal protocol for the ultrastructural examination of skin by transmission electron microscopy. *J. Microsc.* 1997; 187(2): 125-133.
21. Horwitz E, Pisanty S, Czerninski R, Helser M, Eliav E, Touitou E: A clinical evaluation of a novel liposomal carrier for acyclovir in the topical treatment of recurrent herpes labialis. *Oral Surg. Oral Med. Oral Pathol. Oral Radial. Endod.* 1999; 88: 700-705.
22. Jain S, Umamaheshwari R.B, Bhadra D, Jain N.K, Ethosomes- A novel vesicular carrier for enhanced transdermal delivery of an Anti-HIV agents. *Indian J. Pharm. Sci.* 2004; 66(1): 72-81.
23. Esposito E, Menegatti E, Cortesi R: Ethosomes and liposomes as topical vehicles for azelaic acid: a preformulation study. *International Journal of Cosmetic Science* 2004; 26(5): 270.
24. Donatella P, Giuseppe L, Domenico M, Franco A, Massimo F: Ethosomes for skin delivery of ammonium glycyrrhizinate:- In vitro percutaneous permeation through human skin and in-vivo anti-inflammatory activity on human volutrees. *Journal of Controlled Release* 2005; 106(1): 99-110.
25. Goldin B, Touitou E: Mechanism of Bacitracin permeation enhancement through the skin and cellular membrane from an ethosomal carrier. *J. Control. Release* 2004; 94: 365-379.
26. Lodzki M, Godin B, Rakou L, Mechoulam R, Gallily R, Touitou E: Cannabidol transdermal delivery and anti-inflammatory effect in a marine model. *J. Control. Release* 2003; 93: 79-389.
27. Godin B, Touitou E, Rubinstein E, Athamna A, Athamna M: A new approach for treatment of deep skin infections by an ethosomal antibiotic preparation:- an in-vivo study. *Journal of Antimicrobial chemotherapy* 2005; 55(6): 989-994.
28. Kim J.C, Lee M.H, Rang M.J: Minodixil containing dosage forms: skin retention and after rising hair growth promotion. *Drug Delivery* 2003; 10(2): 119-123.
29. Kaplun- Frisckhoff Y, Touitou E: Testosterone skin permeation enhancement by menthol through formation of eutectic with drug and interaction with skin lipids. *J. Pharm. Sci.* 1997; 86: 1394-1399.
